STOCK TITAN
  1. Home
  2. Sec-filings
  3. RANI
  4. [Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity

[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Rani Therapeutics (RANI) reported insider share sales on a Form 4. The reporting person executed open‑market sales of Class A common stock on two dates. On 10/20/2025, they sold 1,923,000 shares at a weighted average price of $2.4115. On 10/21/2025, they sold 4,000,000 shares at a weighted average price of $2.7685.

Following these transactions, the reporting person beneficially owned 2,379,194 shares, held indirectly through South Lake One LLC. The filing notes that the weighted average prices reflect multiple trades within ranges of $2.25–$2.61 and $2.50–$3.09, and detailed trade breakdowns are available upon request. The ownership is reported as indirect, and the form was filed by one reporting person.

Rani Therapeutics (RANI) ha riportato vendite di azioni da parte di insider su un Modulo 4. La persona che segnala ha eseguito vendite sul mercato aperto di azioni comuni di Classe A in due date. Il 10/20/2025, hanno venduto 1.923.000 azioni a un prezzo medio ponderato di $2.4115. Il 10/21/2025, hanno venduto 4.000.000 azioni a un prezzo medio ponderato di $2.7685.

Dopo queste transazioni, la persona che segnala possedeva vantaggiosamente 2.379.194 azioni, detenute indirettamente tramite South Lake One LLC. La relazione nota che i prezzi medi ponderati riflettono molteplici operazioni all'interno degli intervalli di $2,25–$2,61 e $2,50–$3,09, e dettagli di suddivisione delle operazioni sono disponibili su richiesta. La proprietà è riportata come indiretta, e il modulo è stato presentato da una persona che segnala.

Rani Therapeutics (RANI) informó ventas de acciones por insiders en un Formulario 4. La persona reportante ejecutó ventas en el mercado abierto de acciones clase A en dos fechas. El 20/10/2025 vendió 1,923,000 acciones a un precio medio ponderado de $2.4115. El 21/10/2025 vendió 4,000,000 acciones a un precio medio ponderado de $2.7685.

Tras estas operaciones, la persona reportante posee de manera beneficiosa 2,379,194 acciones, de forma indirecta a través de South Lake One LLC. La presentación señala que los precios medios ponderados reflejan múltiples operaciones dentro de rangos de $2.25–$2.61 y $2.50–$3.09, y existen desgloses detallados de operaciones disponibles a solicitud. La titularidad se informa como indirecta, y el formulario fue presentado por una sola persona reportante.

Rani Therapeutics (RANI)는 Form 4에서 내부자 주식 매도를 보고했습니다. 보고자가 두 날짜에 걸쳐 공개시장 매도로 Class A 보통주를 매도했습니다. 2025-10-20에 1,923,000주를 가중 평균가 $2.4115로 매도했습니다. 2025-10-21에 4,000,000주를 가중 평균가 $2.7685로 매도했습니다.

이 거래 후 보고자는 South Lake One LLC를 통해 간접적으로 보유한 2,379,194주의 혜택 소유를 유지합니다. 제출서에는 가중 평균가가 $2.25–$2.61 및 $2.50–$3.09의 여러 거래를 반영한다고 명시되어 있으며, 요청 시 상세 거래 내역을 제공받을 수 있습니다. 소유권은 간접으로 보고되며, 양식은 한 명의 보고자에 의해 제출되었습니다.

Rani Therapeutics (RANI) a signalé des ventes d’actions par des initiés sur un Formulaire 4. La personne déclarante a exécuté des ventes sur le marché libre d’actions ordinaires de catégorie A à deux dates. Le 20/10/2025, elle a vendu 1 923 000 actions à un prix moyen pondéré de $2.4115. Le 21/10/2025, elle a vendu 4 000 000 d’actions à un prix moyen pondéré de $2.7685.

Suite à ces transactions, la personne déclarante détenait avantageusement 2 379 194 actions, détenues indirectement via South Lake One LLC. Le dossier indique que les prix moyens pondérés reflètent plusieurs transactions dans des fourchettes de $2,25–$2,61 et $2,50–$3,09, et des décompositions détaillées des échanges sont disponibles sur demande. La propriété est déclarée comme indirecte, et le formulaire a été déposé par une seule personne déclarant.

Rani Therapeutics (RANI) meldete Insider-Verkäufe in einem Formular 4. Die meldende Person führte Öffentlicher Marktverkäufe von Class A Stammaktien an zwei Terminen durch. Am 20.10.2025 verkaufte sie 1.923.000 Aktien zu einem gewichteten Durchschnittspreis von $2.4115. Am 21.10.2025 verkaufte sie 4.000.000 Aktien zu einem gewichteten Durchschnittspreis von $2.7685.

Nach diesen Transaktionen hielt die meldende Person vorteilhaft 2.379.194 Aktien, indirekt über South Lake One LLC. Die Einreichung vermerkt, dass die gewichteten Durchschnittspreise mehrere Trades innerhalb der Bereiche $2,25–$2,61 und $2,50–$3,09 widerspiegeln, und detaillierte Handelsaufschlüsselungen sind auf Anfrage verfügbar. Die Eigentümerschaft wird als indirekt gemeldet, und das Formular wurde von einer meldenden Person eingereicht.

Rani Therapeutics (RANI) ذكر تقارير insider ببيع أسهم في نموذج 4. نفذ الشخص المبلغ عن هو بيع في السوق المفتوحة لأسهم Class A عادية في تاريخين. في 20/10/2025 باع 1,923,000 سهم بسعر متوسط موزون قدره $2.4115. في 21/10/2025 باع 4,000,000 سهم بسعر متوسط موزون قدره $2.7685.

بعد هذه المعاملات، امتلك الشخص المبلغ عن الملكية بشكل مستفيد 2,379,194 سهمًا، بشكل غير مباشر من خلال South Lake One LLC. يذكر الملف أن الأسعار المتوسطة الموزونة تعكس صفقات متعددة ضمن نطاقي $2.25–$2.61 و $2.50–$3.09، وتتوفر تفصيلات التجارة عند الطلب. تُبلغ الملكية كغير مباشرة، وتم تقديم النموذج من قبل شخص واحد مُبلغ.

Rani Therapeutics (RANI) 在 Form 4 中报告了内幕交易者股票出售。报告人于两日执行了公开市场公开交易的A类普通股出售。2025/10/20，他们以加权平均价格 $2.4115 出售了 1,923,000 股。2025/10/21，他们以加权平均价格 $2.7685 出售了 4,000,000 股。

交易完成后，报告人通过 South Lake One LLC 间接持有 2,379,194 股 的收益所有权。 filing 指出，平均价格反映了在 $2.25–$2.61 和 $2.50–$3.09 区间内的多笔交易，且如需可获取详细交易分解。所有权以间接方式报告，表格由一名报告人提交。

Positive
  • None.
Negative
  • None.

Insights

Large insider sales by a director via an affiliated LLC reduce beneficial holdings; typically a negative governance signal.

A director reported open-market sales of Rani Therapeutics Class A common stock on 10/20/2025 and 10/21/2025. The sales were executed through **South Lake One LLC**, with weighted average prices of $2.4115 (range $2.25–$2.61) for 1,923,000 shares and $2.7685 (range $2.50–$3.09) for 4,000,000 shares.

Following these transactions, the reported beneficial ownership decreased to 2,379,194 Class A shares held indirectly. The filing identifies the ownership chain: **South Cone Investments Limited Partnership** directly owns 100% of the membership interest of **South Lake One LLC**. Transaction code "S" denotes open-market sales. Form 4 timing on 10/22/2025 provides prompt disclosure but does not state a Rule 10b5-1 trading plan.

What to watch: any subsequent Form 4s indicating continued selling, and updated beneficial ownership levels for these affiliated entities. The key near-term marker is whether additional sales occur after 10/21/2025, which would further change the indirect stake. The weighted-average price ranges indicate multiple fills; detailed breakdowns are available upon request per the footnotes.

Rani Therapeutics (RANI) ha riportato vendite di azioni da parte di insider su un Modulo 4. La persona che segnala ha eseguito vendite sul mercato aperto di azioni comuni di Classe A in due date. Il 10/20/2025, hanno venduto 1.923.000 azioni a un prezzo medio ponderato di $2.4115. Il 10/21/2025, hanno venduto 4.000.000 azioni a un prezzo medio ponderato di $2.7685.

Dopo queste transazioni, la persona che segnala possedeva vantaggiosamente 2.379.194 azioni, detenute indirettamente tramite South Lake One LLC. La relazione nota che i prezzi medi ponderati riflettono molteplici operazioni all'interno degli intervalli di $2,25–$2,61 e $2,50–$3,09, e dettagli di suddivisione delle operazioni sono disponibili su richiesta. La proprietà è riportata come indiretta, e il modulo è stato presentato da una persona che segnala.

Rani Therapeutics (RANI) informó ventas de acciones por insiders en un Formulario 4. La persona reportante ejecutó ventas en el mercado abierto de acciones clase A en dos fechas. El 20/10/2025 vendió 1,923,000 acciones a un precio medio ponderado de $2.4115. El 21/10/2025 vendió 4,000,000 acciones a un precio medio ponderado de $2.7685.

Tras estas operaciones, la persona reportante posee de manera beneficiosa 2,379,194 acciones, de forma indirecta a través de South Lake One LLC. La presentación señala que los precios medios ponderados reflejan múltiples operaciones dentro de rangos de $2.25–$2.61 y $2.50–$3.09, y existen desgloses detallados de operaciones disponibles a solicitud. La titularidad se informa como indirecta, y el formulario fue presentado por una sola persona reportante.

Rani Therapeutics (RANI)는 Form 4에서 내부자 주식 매도를 보고했습니다. 보고자가 두 날짜에 걸쳐 공개시장 매도로 Class A 보통주를 매도했습니다. 2025-10-20에 1,923,000주를 가중 평균가 $2.4115로 매도했습니다. 2025-10-21에 4,000,000주를 가중 평균가 $2.7685로 매도했습니다.

이 거래 후 보고자는 South Lake One LLC를 통해 간접적으로 보유한 2,379,194주의 혜택 소유를 유지합니다. 제출서에는 가중 평균가가 $2.25–$2.61 및 $2.50–$3.09의 여러 거래를 반영한다고 명시되어 있으며, 요청 시 상세 거래 내역을 제공받을 수 있습니다. 소유권은 간접으로 보고되며, 양식은 한 명의 보고자에 의해 제출되었습니다.

Rani Therapeutics (RANI) a signalé des ventes d’actions par des initiés sur un Formulaire 4. La personne déclarante a exécuté des ventes sur le marché libre d’actions ordinaires de catégorie A à deux dates. Le 20/10/2025, elle a vendu 1 923 000 actions à un prix moyen pondéré de $2.4115. Le 21/10/2025, elle a vendu 4 000 000 d’actions à un prix moyen pondéré de $2.7685.

Suite à ces transactions, la personne déclarante détenait avantageusement 2 379 194 actions, détenues indirectement via South Lake One LLC. Le dossier indique que les prix moyens pondérés reflètent plusieurs transactions dans des fourchettes de $2,25–$2,61 et $2,50–$3,09, et des décompositions détaillées des échanges sont disponibles sur demande. La propriété est déclarée comme indirecte, et le formulaire a été déposé par une seule personne déclarant.

Rani Therapeutics (RANI) meldete Insider-Verkäufe in einem Formular 4. Die meldende Person führte Öffentlicher Marktverkäufe von Class A Stammaktien an zwei Terminen durch. Am 20.10.2025 verkaufte sie 1.923.000 Aktien zu einem gewichteten Durchschnittspreis von $2.4115. Am 21.10.2025 verkaufte sie 4.000.000 Aktien zu einem gewichteten Durchschnittspreis von $2.7685.

Nach diesen Transaktionen hielt die meldende Person vorteilhaft 2.379.194 Aktien, indirekt über South Lake One LLC. Die Einreichung vermerkt, dass die gewichteten Durchschnittspreise mehrere Trades innerhalb der Bereiche $2,25–$2,61 und $2,50–$3,09 widerspiegeln, und detaillierte Handelsaufschlüsselungen sind auf Anfrage verfügbar. Die Eigentümerschaft wird als indirekt gemeldet, und das Formular wurde von einer meldenden Person eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
South Cone Investments Limited Partnership
(Last) (First) (Middle)
AVENIDA PRESIDENTE RIESCO 5711,
OFICINA 1603, LAS CONDES
(Street)
SANTIAGO F3 7550000
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/20/2025 S 1,923,000 D $2.4115(1) 6,379,194 I Shares indirectly held through South Lake One LLC(2)
Class A Common Stock 10/21/2025 S 4,000,000 D $2.7685(3) 2,379,194 I Shares indirectly held through South Lake One LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.25 to $2.61, inclusive. The reporting person undertakes to provide to Rani Therapeutics Holdings, Inc. ("Rani"), any security holder of Rani, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC.
3. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.50 to $3.09, inclusive. The reporting person undertakes to provide to Rani, any security holder of Rani, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Martin Abraham Guiloff Salvador and /s/ Luis Felipe Correa Gonzalez, Managers of South Lake One LLC 10/22/2025
/s/ Martin Abraham Guiloff Salvador and /s/ Luis Felipe Correa Gonzalez, Managers of South Lake Management LLC, as General Partner of South Cone Investments Limited Partnership 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions were reported for RANI?

Open‑market sales of Class A common stock on 10/20/2025 and 10/21/2025 totaling 5,923,000 shares were reported.

At what prices were the RANI shares sold?

Weighted average prices were $2.4115 on 10/20/2025 and $2.7685 on 10/21/2025, across ranges of $2.25–$2.61 and $2.50–$3.09.

How many RANI shares does the reporting person own after the sales?

After the transactions, the reporting person beneficially owned 2,379,194 shares.

How is the ownership of RANI shares held by the reporting person structured?

Ownership is indirect, with shares held through South Lake One LLC.

Who can request detailed trade information for the reported RANI sales?

Rani Therapeutics, any Rani security holder, or SEC staff may request full trade details, per the filing’s footnotes.

Was the Form 4 filed by one or multiple reporting persons?

The form indicates it was filed by one reporting person.
Stock RANI logo
Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

RANI Rankings

#4638 Ranked by Market Cap
N/A Ranked by Dividends

RANI Latest News

Oct 17, 2025
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Oct 17, 2025
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Aug 7, 2025
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
Jul 15, 2025
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Jul 14, 2025
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

RANI Latest SEC Filings

Oct 17, 2025
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event
Aug 14, 2025
[SCHEDULE 13G] Rani Therapeutics Holdings, Inc. SEC Filing
Aug 8, 2025
[S-3] Rani Therapeutics Holdings, Inc. Shelf Registration Statement
Aug 7, 2025
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event
Aug 5, 2025
[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity

RANI Stock Data

136.51M
38.54M
19.56%
17.01%
0.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN JOSE